Spero Therapeutics Toekomstige groei

Future criteriumcontroles 3/6

De omzet van Spero Therapeutics zal naar verwachting dalen met 13.4% per jaar, terwijl de jaarlijkse winst naar verwachting zal groeien met 40.4% per jaar. De winst per aandeel zal naar verwachting groeien met 35.2% per jaar.

Belangrijke informatie

40.4%

Groei van de winst

35.2%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	-13.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Recent updates

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Nov 02

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Winst- en omzetgroeiprognoses

NasdaqGS:SPRO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	6	-25	-23	-22	2
12/31/2025	18	-42	N/A	-47	3
12/31/2024	33	-72	N/A	-46	2
9/30/2024	106	4	-18	-18	N/A
6/30/2024	118	17	-14	-14	N/A
3/31/2024	111	23	-14	-14	N/A
12/31/2023	104	23	-33	-33	N/A
9/30/2023	78	-2	29	29	N/A
6/30/2023	54	-10	12	12	N/A
3/31/2023	54	-27	8	8	N/A
12/31/2022	54	-46	-8	-8	N/A
9/30/2022	9	-102	-80	-80	N/A
6/30/2022	10	-113	-84	-84	N/A
3/31/2022	13	-103	-77	-77	N/A
12/31/2021	18	-90	-64	-64	N/A
9/30/2021	17	-79	-53	-53	N/A
6/30/2021	18	-76	-70	-70	N/A
3/31/2021	15	-74	-78	-78	N/A
12/31/2020	9	-79	-86	-86	N/A
9/30/2020	11	-85	-87	-87	N/A
6/30/2020	12	-84	-75	-75	N/A
3/31/2020	12	-80	-63	-62	N/A
12/31/2019	18	-61	-50	-50	N/A
9/30/2019	16	-47	-49	-46	N/A
6/30/2019	12	-39	-45	-42	N/A
3/31/2019	11	-36	-41	-39	N/A
12/31/2018	4	-42	-42	-40	N/A
9/30/2018	3	-46	-39	-39	N/A
6/30/2018	3	-47	N/A	-44	N/A
3/31/2018	3	-50	N/A	-44	N/A
12/31/2017	2	-46	N/A	-39	N/A
9/30/2017	1	-40	N/A	-36	N/A
6/30/2017	1	-35	N/A	-32	N/A
3/31/2017	0	-30	N/A	-29	N/A
12/31/2016	0	-30	N/A	-29	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei SPRO ( 40.4% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van SPRO ( 40.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van SPRO zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van SPRO zal naar verwachting de komende 3 jaar dalen ( -13.4% per jaar).

Hoge groei-inkomsten: De omzet van SPRO zal naar verwachting de komende 3 jaar dalen ( -13.4% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SPRO naar verwachting over 3 jaar hoog zal zijn

Spero Therapeutics Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 18%, revenue upgraded

Consensus revenue estimates increase by 15%

Price target decreased by 20% to US$6.00

Consensus EPS estimates fall by 46%

Consensus EPS estimates upgraded to US$1.09 loss

Consensus revenue estimates fall by 50%

Recent updates

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 18%, revenue upgraded

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CFO, Chief Business Officer & Treasurer recently sold US$53k worth of stock

Consensus revenue estimates increase by 15%

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Price target decreased by 20% to US$6.00

Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 46%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Consensus EPS estimates upgraded to US$1.09 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 50%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Investor sentiment improves as stock rises 15%

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates fall by 24%

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

President notifies of intention to sell stock

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 21%, EPS downgraded

Price target increased by 18% to US$7.50

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Consensus estimates of losses per share improve by 10%

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Consensus estimates of losses per share improve by 38%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 35%

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Consensus revenue estimates fall by 36%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 53%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Consensus revenue estimates increase by 183%

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics appoints Kamal Hamed MD CMO

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Consensus revenue estimates increase by 69%